269 related articles for article (PubMed ID: 35836807)
1. SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways.
Ma L; Zou R; Shi W; Zhou N; Chen S; Zhou H; Chen X; Wu Y
Theranostics; 2022; 12(11):5034-5050. PubMed ID: 35836807
[No Abstract] [Full Text] [Related]
2. Ripk3 regulates cardiac microvascular reperfusion injury: The role of IP3R-dependent calcium overload, XO-mediated oxidative stress and F-action/filopodia-based cellular migration.
Zhou H; Wang J; Zhu P; Hu S; Ren J
Cell Signal; 2018 May; 45():12-22. PubMed ID: 29413844
[TBL] [Abstract][Full Text] [Related]
3. Empagliflozin attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial homeostasis.
Zou R; Shi W; Qiu J; Zhou N; Du N; Zhou H; Chen X; Ma L
Cardiovasc Diabetol; 2022 Jun; 21(1):106. PubMed ID: 35705980
[TBL] [Abstract][Full Text] [Related]
4. BI1 alleviates cardiac microvascular ischemia-reperfusion injury via modifying mitochondrial fission and inhibiting XO/ROS/F-actin pathways.
Zhou H; Wang J; Hu S; Zhu H; Toanc S; Ren J
J Cell Physiol; 2019 Apr; 234(4):5056-5069. PubMed ID: 30256421
[TBL] [Abstract][Full Text] [Related]
5. Empagliflozin attenuates cardiac microvascular ischemia/reperfusion through activating the AMPKα1/ULK1/FUNDC1/mitophagy pathway.
Cai C; Guo Z; Chang X; Li Z; Wu F; He J; Cao T; Wang K; Shi N; Zhou H; Toan S; Muid D; Tan Y
Redox Biol; 2022 Jun; 52():102288. PubMed ID: 35325804
[TBL] [Abstract][Full Text] [Related]
6. Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells.
Uthman L; Homayr A; Juni RP; Spin EL; Kerindongo R; Boomsma M; Hollmann MW; Preckel B; Koolwijk P; van Hinsbergh VWM; Zuurbier CJ; Albrecht M; Weber NC
Cell Physiol Biochem; 2019; 53(5):865-886. PubMed ID: 31724838
[TBL] [Abstract][Full Text] [Related]
7. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
[TBL] [Abstract][Full Text] [Related]
8. Protective effect of HINT2 on mitochondrial function via repressing MCU complex activation attenuates cardiac microvascular ischemia-reperfusion injury.
Li S; Chen J; Liu M; Chen Y; Wu Y; Li Q; Ma T; Gao J; Xia Y; Fan M; Chen A; Lu D; Su E; Xu F; Chen Z; Qian J; Ge J
Basic Res Cardiol; 2021 Dec; 116(1):65. PubMed ID: 34914018
[TBL] [Abstract][Full Text] [Related]
9. Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury.
Lahnwong C; Palee S; Apaijai N; Sriwichaiin S; Kerdphoo S; Jaiwongkam T; Chattipakorn SC; Chattipakorn N
Cardiovasc Diabetol; 2020 Jun; 19(1):91. PubMed ID: 32539724
[TBL] [Abstract][Full Text] [Related]
10. Adiponectin regulates SR Ca(2+) cycling following ischemia/reperfusion via sphingosine 1-phosphate-CaMKII signaling in mice.
Yan W; Zhang F; Zhang R; Zhang X; Wang Y; Zhou F; Xia Y; Liu P; Gao C; Wang H; Zhang L; Zhou J; Gao F; Gao E; Koch WJ; Wang H; Cheng H; Qu Y; Tao L
J Mol Cell Cardiol; 2014 Sep; 74():183-92. PubMed ID: 24852843
[TBL] [Abstract][Full Text] [Related]
11. Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium.
Cappetta D; De Angelis A; Ciuffreda LP; Coppini R; Cozzolino A; Miccichè A; Dell'Aversana C; D'Amario D; Cianflone E; Scavone C; Santini L; Palandri C; Naviglio S; Crea F; Rota M; Altucci L; Rossi F; Capuano A; Urbanek K; Berrino L
Pharmacol Res; 2020 Jul; 157():104781. PubMed ID: 32360273
[TBL] [Abstract][Full Text] [Related]
12. The histone deacetylase inhibitor SAHA exerts a protective effect against myocardial ischemia/reperfusion injury by inhibiting sodium-calcium exchanger.
Shi X; Yin Y; Guo X; Liu M; Ma F; Tian L; Zheng M; Liu G
Biochem Biophys Res Commun; 2023 Sep; 671():105-115. PubMed ID: 37300940
[TBL] [Abstract][Full Text] [Related]
13. Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF-β/Smad signalling in type 2 diabetic rats.
Tian J; Zhang M; Suo M; Liu D; Wang X; Liu M; Pan J; Jin T; An F
J Cell Mol Med; 2021 Aug; 25(16):7642-7659. PubMed ID: 34169635
[TBL] [Abstract][Full Text] [Related]
14. Direct cardio-protection of Dapagliflozin against obesity-related cardiomyopathy via NHE1/MAPK signaling.
Lin K; Yang N; Luo W; Qian JF; Zhu WW; Ye SJ; Yuan CX; Xu DY; Liang G; Huang WJ; Shan PR
Acta Pharmacol Sin; 2022 Oct; 43(10):2624-2635. PubMed ID: 35217813
[TBL] [Abstract][Full Text] [Related]
15. Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect?
Nikolaou PE; Mylonas N; Makridakis M; Makrecka-Kuka M; Iliou A; Zerikiotis S; Efentakis P; Kampoukos S; Kostomitsopoulos N; Vilskersts R; Ikonomidis I; Lambadiari V; Zuurbier CJ; Latosinska A; Vlahou A; Dimitriadis G; Iliodromitis EK; Andreadou I
Basic Res Cardiol; 2022 May; 117(1):27. PubMed ID: 35581445
[TBL] [Abstract][Full Text] [Related]
16. Dapagliflozin alleviates myocardial ischemia/reperfusion injury by reducing ferroptosis
Chen W; Zhang Y; Wang Z; Tan M; Lin J; Qian X; Li H; Jiang T
Front Pharmacol; 2023; 14():1078205. PubMed ID: 36891270
[TBL] [Abstract][Full Text] [Related]
17. Dapagliflozin attenuates hypoxia/reoxygenation-caused cardiac dysfunction and oxidative damage through modulation of AMPK.
Tsai KL; Hsieh PL; Chou WC; Cheng HC; Huang YT; Chan SH
Cell Biosci; 2021 Feb; 11(1):44. PubMed ID: 33637129
[TBL] [Abstract][Full Text] [Related]
18. Chronic Empagliflozin Treatment Reduces Myocardial Infarct Size in Nondiabetic Mice Through STAT-3-Mediated Protection on Microvascular Endothelial Cells and Reduction of Oxidative Stress.
Nikolaou PE; Efentakis P; Abu Qourah F; Femminò S; Makridakis M; Kanaki Z; Varela A; Tsoumani M; Davos CH; Dimitriou CA; Tasouli A; Dimitriadis G; Kostomitsopoulos N; Zuurbier CJ; Vlahou A; Klinakis A; Brizzi MF; Iliodromitis EK; Andreadou I
Antioxid Redox Signal; 2021 Mar; 34(7):551-571. PubMed ID: 32295413
[No Abstract] [Full Text] [Related]
19. Effect of dapagliflozin on ferroptosis through the gut microbiota metabolite TMAO during myocardial ischemia-reperfusion injury in diabetes mellitus rats.
Wang L; Wang Y; Xu H; Li W
Sci Rep; 2024 Jun; 14(1):13851. PubMed ID: 38879701
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of the zinc transporter SLC39A13 (ZIP13) is responsible for the activation of CaMKII at reperfusion and leads to myocardial ischemia/reperfusion injury in mouse hearts.
Wang J; Cheng X; Zhao H; Yang Q; Xu Z
J Mol Cell Cardiol; 2021 Mar; 152():69-79. PubMed ID: 33307093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
